

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ARGENTUM PHARMACEUTICALS LLC,
Petitioner,

v.

RESEARCH CORPORATION TECHNOLOGIES, INC.,
Patent Owner.

Case No. IPR2016-00204
Patent No. RE 38,551

**PATENT OWNER PRELIMINARY RESPONSE
PURSUANT TO 37 C.F.R. § 42.107**

LIST OF EXHIBITS

| Exhibit | Description |
|----------------|---|
| 2001 | Richard H. Mattson, <i>Efficacy and Adverse Effects of Established and New Antiepileptic Drugs</i> , 36 (Suppl. 2) <i>Epilepsia</i> S13-S26 (1995). |
| 2002 | Richard H. Mattson, <i>Drug Treatment of Uncontrolled Seizures, in Surgical Treatment of Epilepsy</i> 29-35 (William H. Theodore ed., 1992). |
| 2003 | FDA Approved Labeling Text dated August 27, 2012 for FELBATOL [®] (felbamate) , <i>available at</i> http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf (last visited Feb. 2, 2016). |
| 2004 | Judith D. Conley & Harold Kohn, <i>Functionalized DL-Amino Acid Derivatives. Potent New Agents for the Treatment of Epilepsy</i> , 30 <i>J. Med. Chem.</i> 567-574 (1987). |
| 2005 | U.S. Provisional Patent Application No. 60/013,522. |
| 2006 | Bialer <i>et al.</i> , <i>Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)</i> , 51 <i>Epilepsy Res.</i> 31-71 (2002). |
| 2007 | Jerry March, <i>Advanced Organic Chemistry</i> 94-96 (4th ed. 1992). |
| 2008 | Decision Denying Institution of <i>Inter Partes</i> Review, IPR2014-01126, Paper 22. |
| 2009 | Curriculum Vitae of Dr. Farrokh Mistree, September 2014. |
| 2010 | Marcy Barge & W.T. Ingram, <i>Inverse Limits on [0,1] Using Logistic Bonding Maps</i> , 72 <i>Topology and its Applications</i> 159-72 (1996). |
| 2011 | Jack McBryde Jr., <i>Inverse Limits on Arcs Using Certain Logistic Maps as Bonding Maps</i> , Master's Thesis, University of Houston, (1987). |
| 2012 | Trial Testimony of Dr. Clayton Heathcock, <i>UCB, Inc., et al., v. Accord Healthcare, Inc., et al.</i> , No. 13-1206-LPS (D. Del., Nov. 9, 2015). |

| Exhibit | Description |
|---------|---|
| 2013 | FDA Approved Labeling Text dated July 9, 2015 for VIMPAT [®] (lacosamide), <i>available at</i> http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022253s030,022254s022,022255s016lbl.pdf (last visited Feb. 2, 2016). |
| 2014 | Wolfgang Löscher & Dieter Schmidt, <i>Strategies in Antiepileptic Drug Development: Is Rational Drug Design Superior to Random Screening and Structural Variation?</i> , 17 <i>Epilepsy Research</i> 95-134 (1994). |
| 2015 | Michael A. Rogawski & Roger J. Porter, <i>Antiepileptic Drugs: Pharmacological Mechanisms and Clinical Efficacy with Consideration of Promising Developmental Stage Compounds</i> , 42(3) <i>Pharmacological Reviews</i> 223-86 (1990). |
| 2016 | John M. Pellock, <i>Standard Approach to Antiepileptic Drug Treatment in the United States</i> 35 (Suppl. 4) <i>Epilepsia</i> S11-S18 (1994). |
| 2017 | Approval Listing dated December 27, 1994 for lamotrigine, Approved Drug Products with Therapeutic Equivalence Evaluations (Electronic Orange Book), http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=020241&TABLE1=OB_Rx (last visited Feb. 2, 2016). |
| 2018 | The Merck Index 77, 290, 404, 407, 408, 508, 640, 670, 733, 915, 998, 999, 1020, 1028, 1207, 1246, 1247, 1251, 1259, 1260, 1330, 1654 (Susan Budavari et al. eds., 12th ed. 1996). |
| 2019 | Approval Listing dated August 5, 1996 for fosphenytoin sodium, Approved Drug Products with Therapeutic Equivalence Evaluations (Electronic Orange Book), http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=020450&TABLE1=OB_Rx (last visited Feb. 2, 2016). |
| 2020 | FDA Approved Labeling Text dated January 2014 for CEREBYX [®] (fosphenytoin sodium injection) , <i>available at</i> http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020450s023lbl.pdf (last visited Feb. 2, 2016). |

| Exhibit | Description |
|---------|---|
| 2021 | ChemIDPlus, Toxnet, U.S. Nat'l Library of Medicine, Beclamide, http://chem.sis.nlm.nih.gov/chemidplus/rn/501-68-8 (last visited Feb. 2, 2016). |
| 2022 | ChemIDPlus, Toxnet, U.S. Nat'l Library of Medicine, Phenacemide, http://chem.sis.nlm.nih.gov/chemidplus/rn/63-98-9 (last visited Feb. 2, 2016). |
| 2023 | ChemIDPlus, Toxnet, U.S. Nat'l Library of Medicine, Valproic acid, http://chem.sis.nlm.nih.gov/chemidplus/rn/99-66-1 (last visited Feb. 2, 2016). |
| 2024 | Portfolio – Mont Alto Capital, http://www.montaltocapital.com/portfolio/ (last visited Feb. 23, 2016) |

TABLE OF CONTENTS

| | Page(s) |
|--|----------------|
| I. Introduction..... | 1 |
| II. The Development of the Inventions and the ‘551 Patent..... | 4 |
| III. Level of Ordinary Skill in the Art | 9 |
| IV. Claim Construction Under “Broadest Reasonable Interpretation” | 9 |
| A. “A Compound In the R Configuration” | 10 |
| B. “Therapeutic Composition”..... | 13 |
| V. Petitioner Fails to Demonstrate a Reasonable Likelihood That at Least One Claim of the ‘551 Patent Is Unpatentable..... | 17 |
| A. Grounds 1A and 1B Should be Denied Under 35 U.S.C. § 325(d) | 17 |
| 1. The Board Has Already Decided That the LeGall Thesis Does Not Qualify as a Printed Publication | 18 |
| 2. The Petition Provides No Credible Evidence of Public Accessibility of the LeGall Thesis To Justify Reversal of the Board’s Prior Ruling | 19 |
| B. Ground 1A: Petitioner Fails to Show That the LeGall Thesis Anticipates Any of Claims 1 and 3-8..... | 23 |
| C. Ground 1B: Petitioner Fails to Show That Claims 2 and 9-13 are Unpatentable Over the LeGall Thesis and the ‘729 Patent..... | 26 |
| 1. Claims 2 and 9..... | 26 |
| 2. Claim 10..... | 36 |
| 3. Claims 11-13 | 38 |
| D. Grounds 2A and 2B: Petitioner Fails to Show That Claims 1-13 are Unpatentable Over Choi, Kohn 1991, and the ‘729 Patent..... | 40 |

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.